Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
about
Strategies to Identify and Reduce Opioid Misuse Among Patients with Gastrointestinal Disorders: A Systematic Scoping Review.Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease.Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro.
P2860
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@en
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@nl
type
label
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@en
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@nl
prefLabel
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@en
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@nl
P2860
P1476
Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.
@en
P2093
Benjamin Click
David G Binion
P2860
P304
P356
10.1016/J.CGH.2016.11.027
P407
P577
2016-12-03T00:00:00Z